Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct 11;27(11):111153.
doi: 10.1016/j.isci.2024.111153. eCollection 2024 Nov 15.

Fatty acid abnormalities in cystic fibrosis-the missing link for a cure?

Sławomira Drzymała-Czyż  1 , Jarosław Walkowiak  2 , Carla Colombo  3 , Gianfranco Alicandro  3 , Olav Trond Storrösten  4 , Magnhild Kolsgaard  4 , Egil Bakkeheim  4 , Birgitta Strandvik  5
Affiliations
Review

Fatty acid abnormalities in cystic fibrosis-the missing link for a cure?

Sławomira Drzymała-Czyż et al. iScience. .

Abstract

The care for cystic fibrosis (CF) has dramatically changed with the development of modulators, correctors, and potentiators of the CFTR molecule, which lead to improved clinical status of most people with CF (pwCF). The modulators influence phospholipids and ceramides, but not linoleic acid (LA) deficiency, associated with more severe phenotypes of CF. The LA deficiency is associated with upregulation of its transfer to arachidonic acid (AA). The AA release from membranes is increased and associated with increase of pro-inflammatory prostanoids and the characteristic inflammation is present before birth and bacterial infections. Docosahexaenoic acid is often decreased, especially in associated liver disease Some endogenously synthesized fatty acids are increased. Cholesterol and ceramide metabolisms are disturbed. The lipid abnormalities are present at birth, and before feeding in transgenic pigs and ferrets. This review focus on the lipid abnormalities and their associations to clinical symptoms in CF, based on clinical studies and experimental research.

Keywords: Clinical genetics; Health sciences; Human genetics; Internal medicine; Medical specialty; Medicine; Molecular biology; Respiratory medicine.

PubMed Disclaimer

Conflict of interest statement

J.W. reports personal fees and non-financial support from Biocodex, BGP Products, Chiesi, Hipp, Humana, Mead Johnson Nutrition, Merck Sharp & Dohme, Nestle, Norsa Pharma, Nutricia, Roche, Sequoia Pharmaceuticals, and Vitis Pharma, outside the submitted work, and grants, personal fees and non-financial support from Nutricia Research Foundation Poland, all outside the submitted work. None of the other authors declare any conflicts of interest. Financial support for discussion meetings was received from European Society of Pediatric Gastroenterology, Hepatology and Nutrition and from the Swedish Cystic Fibrosis Association. No competing interest are reported by the authors.

Figures

None
Graphical abstract
Figure 1
Figure 1
A basic simplified overview of the hypothetical relation between fatty acid abnormalities in relation to CFTR and clinical implications CFTR must fit in the membrane for normal function. CFTR variants are processed in the cell and abnormal CFTR are sorted in the endoplasmic reticulum, where most aberrant CFTR is withdrawn, and not all reach the membranes where the localization or function may be impaired in the context of membrane lipids. In normal cells glucocorticoids interfere with the annexin synthesis, which possibly by phosphorylation regulate PLA2 activity by inhibition both of its release of arachidonic acid and activity of COX 2 for PGE2 release. In CF down-regulation of annexin synthesis increases arachidonic acid release with subsequent increasing synthesis from linoleic acid. Thereby linoleic decreases in the membranes interfering with the membrane stereochemistry hampering CFTR activity, and thus impairing the action between CFTR and membranes. Fatty acid composition differs in membranes and organelles, whereby the defective CFTR transfer/function might occur in different compartment localizations in cells and organs. Defective metabolism of ceramides and cholesterol interferes with the raft building (not shown), where the CFTR have its action. Low DHA have been described in cystic fibrosis liver disease (CFRLD) and may be connected with cystic fibrosis related diabetes (CFRD) and may be related to low LXA4. The boxes to the left summarize lipid related processes described in the section “associations between clinical symptoms and fatty acid balance”. GR, Glucocorticoid Receptor; AA, arachidonic acid; ER, endoplasmic reticulum; LA, linoleic acid; PLA2, phospholipase A2,; PGE2, prostaglandin E2; LXA4, lipoxin A4. Differences in arrow size reflect relative transfer activity.
See this image and copyright information in PMC

References

    1. Rubin B.K. Unmet needs in cystic fibrosis. Expet Opin. Biol. Ther. 2018;18:49–52. doi: 10.1080/14712598.2018.1484101. - DOI - PubMed
    1. West N.E., Flume P.A. Unmet needs in cystic fibrosis: the next steps in improving outcomes. Expet Rev. Respir. Med. 2018;12:585–593. doi: 10.1080/17476348.2018.1483723. - DOI - PMC - PubMed
    1. Gabbi C., Warner M., Gustafsson J.A. Minireview: liver X receptor beta: emerging roles in physiology and diseases. Mol. Endocrinol. 2009;23:129–136. doi: 10.1210/me.2008-0398. - DOI - PMC - PubMed
    1. Sweed N., Kim H.J., Hultenby K., Barros R., Parini P., Sancisi V., Strandvik B., Gabbi C. Liver X receptor β regulates bile volume and the expression of aquaporins and cystic fibrosis transmembrane conductance regulator in the gallbladder. Am. J. Physiol. Gastrointest. Liver Physiol. 2021;321 doi: 10.1152/ajpgi.00024.2021. G243-g251. - DOI - PMC - PubMed
    1. Mall M., Grubb B.R., Harkema J.R., O'Neal W.K., Boucher R.C. Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice. Nat. Med. 2004;10:487–493. doi: 10.1038/nm1028. - DOI - PubMed